Study examines technological capacity and innovation

[ishanijerin1]

Biotechnology, especially for human health, offers countless opportunities for learning and accumulating technological capabilities for significant innovations with very high added value.

The study “Accumulation of Technological Capacity for Innovation in Biotechnology Companies for Human Health in Brazil: Exploratory Analysis and Practical Recommendations” is a pioneering study in Brazil and one of the most innovative at an international level. Coordinated by Paulo Negreiros Figueiredo, professor at the Brazilian School of Public and Business Administration (FGV EBAPE), the research is highly relevant to Brazil for the following reasons:

First, biotechnology, especially for human health, offers numerous opportunities for learning and accumulating technological capabilities for significant and vp manufacturing production email database high-value-added innovations, particularly in developing countries. Developing capabilities for innovation in biotechnology for human health at the national level contributes to the much-needed structural transformation of the Brazilian economy .

Second, accumulating technological capabilities for innovation in biotechnology for human health in Brazilian companies has important socioeconomic implications :

With a population of 203 million and a universal public health system, the Unified Health System (SUS), based on the Federal Constitution, there has been a growing demand for government spending on public health services in Brazil. Demographic factors and new therapies available through the SUS have increased the demand for biotechnology drugs and active pharmaceutical ingredients (APIs).

During the critical phase of the COVID-19 pandemic, Brazil's imports of inputs and technology reached approximately USD 20 billion. Limited domestic supply has led to a substantial increase in Brazil's imports of biopharmaceuticals and APIs, generating a continuous trade deficit.
Funded by CNPq (Universal Call), the study lasted three years. This unprecedented (and challenging) study produced new evidence and analyses, with an adequate level of detail and depth, which serve as input for government and business actions aimed at the growth and strengthening of biotechnology activities for human health in Brazil, through the accumulation of technological capabilities for significant innovations.

Based on an innovative methodology, the study identified levels of technological capacity for innovation, its main sources and impacts, in a set of 30 Brazilian biotechnology companies for human health, including startups and established pharmaceutical companies.